Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADMIRE: Maintenance therapy with biologics plus irinotecan versus biologics plus 5-FU/LV for metastatic colorectal cancer
KCT0008619Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan, fluorouracil, folinic acid in metastatic colon cancer (mCRC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
irinotecanfluorouracilfolinic acid
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on KCT0008619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008619.